Hidehisa Saeki

Professor

Nippon Medical School

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hidehisa Saeki is a Professor at Nippon Medical School in Japan. His research primarily focuses on the treatment and management of psoriasis and atopic dermatitis, as demonstrated in his recent publications. He has investigated the efficacy and safety of various treatments, including bimekizumab and delgocitinib, and has contributed to understanding patient satisfaction and real-world outcomes in these areas.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (2)

Akimichi Morita

JAPAN

View details

Sei‐ichiro Motegi

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hidehisa Saeki

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study

A 104‐Week Real‐World Outcome of Bimekizumab Treatment for Psoriasis: Biologic‐Naïve Versus ‐Experienced Patients

Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis

Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis‐Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment

Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy

A Case of Stevens–Johnson Syndrome Induced by Selpercatinib

A predictive factor of oral candidiasis in psoriasis patients treated with bimekizumab: Longer disease duration

Long‐term maintenance of responses to bimekizumab treatment in moderate‐to‐severe psoriasis: A real‐world comparison of Q4W versus Q8W dosing or bio‐naïve versus bio‐switched patients

Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance

Collaborators (2)

Akimichi Morita

Sei‐ichiro Motegi

Make your next move.